[HTML][HTML] Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month …
ED Bateman, KR Chapman, D Singh, AD D'Urzo… - Respiratory …, 2015 - Springer
Background The combination of aclidinium bromide, a long-acting anticholinergic, and
formoterol fumarate, a long-acting beta 2-agonist (400/12 μg twice daily) achieves …
formoterol fumarate, a long-acting beta 2-agonist (400/12 μg twice daily) achieves …
Bronchodilator reversibility testing in chronic obstructive pulmonary disease
PMA Calverley, PS Burge, S Spencer, JA Anderson… - Thorax, 2003 - thorax.bmj.com
Background: A limited or absent bronchodilator response is used to classify chronic
obstructive pulmonary disease (COPD) and can determine the treatment offered. The …
obstructive pulmonary disease (COPD) and can determine the treatment offered. The …
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
A Agustí, L de Teresa, W De Backer… - European …, 2014 - Eur Respiratory Soc
Fluticasone furoate/vilanterol trifenatate (FF/VI) is a once-daily inhaled corticosteroid/long-
acting β2-agonist combination in development for chronic obstructive pulmonary disease …
acting β2-agonist combination in development for chronic obstructive pulmonary disease …
[HTML][HTML] Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial
FJ Martinez, KF Rabe, GT Ferguson, JA Wedzicha… - Respiratory …, 2021 - Elsevier
Background We report the long-term effects of triple therapy with budesonide/glycopyrrolate/
formoterol fumarate (BGF) vs glycopyrrolate/formoterol fumarate (GFF) and …
formoterol fumarate (BGF) vs glycopyrrolate/formoterol fumarate (GFF) and …
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study
RA Stockley, N Chopra, L Rice - Thorax, 2006 - thorax.bmj.com
Background: This study investigated the addition of salmeterol to existing treatment for
exacerbations in patients with poorly reversible chronic obstructive pulmonary disease …
exacerbations in patients with poorly reversible chronic obstructive pulmonary disease …
[HTML][HTML] Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use
M Decramer, R Dahl, O Kornmann, S Korn… - Respiratory …, 2013 - Elsevier
BACKGROUND: Indacaterol is a once-daily, long-acting β2-agonist bronchodilator that
improves dyspnoea and health status in patients with moderate-to-severe COPD. While its …
improves dyspnoea and health status in patients with moderate-to-severe COPD. While its …
The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD
NA Hanania, P Darken, D Horstman, C Reisner, B Lee… - Chest, 2003 - Elsevier
Study objectives: To compare the efficacy and safety of the inhaled corticosteroid fluticasone
propionate (FP) and the inhaled long-acting β 2-agonist salmeterol (SM), when administered …
propionate (FP) and the inhaled long-acting β 2-agonist salmeterol (SM), when administered …
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes
A Anzueto, GT Ferguson, G Feldman… - COPD: Journal of …, 2009 - Taylor & Francis
Prevention and treatment of COPD exacerbations are recognized as key goals in disease
management. This randomized, double-blind, parallel-group, multicenter study evaluated …
management. This randomized, double-blind, parallel-group, multicenter study evaluated …
Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD
DD Briggs Jr, H Covelli, R Lapidus… - Pulmonary …, 2005 - Elsevier
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommends long-acting bronchodilators as first-line maintenance treatment for patients …
recommends long-acting bronchodilators as first-line maintenance treatment for patients …
Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility
D Bouros, J Kottakis, VL Gros, T Overend… - … medical research and …, 2004 - Taylor & Francis
Background: Recent studies suggest that inspiratory capacity (IC) measured at rest can be
used to predict improvements in dyspnea and exercise tolerance in chronic obstructive …
used to predict improvements in dyspnea and exercise tolerance in chronic obstructive …